At the news
? NEUTRALIMPACT 2/10 PRESS-RELEASE filed Jun 19, 2026 at 17:15 ET
Iovance Biotherapeutics granted inducement stock options covering 140,860 shares to 27 new non-executive employees under its 2021 Inducement Plan, with an exercise price of $3.91 per share and a three-year vesting schedule. This is a routine equity grant to attract new hires and has no material impact on the company's financials or operations.
- Granted inducement stock options for 140,860 shares to 27 new non-executive employees.
- Exercise price set at $3.91, the closing price on June 18, 2026.
- Options vest over three years: one-third on first anniversary, remainder in quarterly installments.
- Granted under Iovance's Amended and Restated 2021 Inducement Plan per Nasdaq Listing Rule 5635(c)(4).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access